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Abstract: Accurate prediction of the potential hepatotoxic nature of new pharmaceuticals remains
highly challenging. Therefore, novel in vitro models with improved external validity are needed to
investigate hepatic metabolism and timely identify any toxicity of drugs in humans. In this study, we
examined the effects of diclofenac, as a model substance with a known risk of hepatotoxicity in vivo,
in a dynamic multi-compartment bioreactor using primary human liver cells. Biotransformation
pathways of the drug and possible effects on metabolic activities, morphology and cell transcriptome
were evaluated. Formation rates of diclofenac metabolites were relatively stable over the application
period of seven days in bioreactors exposed to 300 µM diclofenac (300 µM bioreactors (300 µM
BR)), while in bioreactors exposed to 1000 µM diclofenac (1000 µM BR) metabolite concentrations
declined drastically. The biochemical data showed a significant decrease in lactate production and for
the higher dose a significant increase in ammonia secretion, indicating a dose-dependent effect of
diclofenac application. The microarray analyses performed revealed a stable hepatic phenotype of
the cells over time and the observed transcriptional changes were in line with functional readouts of
the system. In conclusion, the data highlight the suitability of the bioreactor technology for studying
the hepatotoxicity of drugs in vitro.
Keywords: primary human hepatocytes, in vitro hepatotoxicity model; three-dimensional (3D)
bioreactor; diclofenac
1. Introduction
To date, there is an unmet need towards innovative in vitro liver models enabling clinical
translation of laboratory research. Each new drug has to undergo extensive preclinical testing before
entering clinical trials, and on average only one out of nine developed compounds receives approval by
the regulatory authorities [1]. Animal models and in vitro models are both currently used to investigate
pharmacodynamics and pharmacokinetics of new drugs. A major limitation of animal models is
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the insufficient prediction of human drug effects due to species-dependent differences in hepatic
metabolism and different sensitivity to toxic effects [2]. In vitro culture models provide an option to
address this limitation by using human liver cells. Human hepatoma cell lines were suggested as
a potential human cell source for in vitro studies due to their high proliferation capacity and good
availability [3,4], but aberrations in specific metabolic enzymes can alter bioactivation processes in
pharmacological studies. The generation of hepatocytes from human stem cells, such as embryonic
or induced pluripotent stem cells, holds large potential for future applications but currently lacks
robust protocols for generating hepatocyte-like cells with a sufficiently mature hepatic phenotype [5].
Thus, primary human hepatocytes (pHH) are currently deemed as the gold standard to provide
human-predictive data on hepatic metabolism and toxicity of new drugs [6].
The commonly used two-dimensional (2D) cultures of pHH are characterized by a lack of cell–cell
contacts and paracrine signaling resulting in a rapid loss of metabolic functions [7,8]. To overcome
the limitations of classical 2D culture systems, various 2D co-culture and 3D culture systems for
cultivation of pHH were developed to improve the long-term maintenance and functionality of
the cells in vitro [9–11]. Our approach is based on a 3D multi-compartment hollow-fiber bioreactor
technology (Figure 1) for high-density perfusion culture of pHH in co-culture with non-parenchymal
liver cells [12]. Tissue-like cell reorganization and stable cell maintenance over at least two weeks were
observed using different scales of the technology [13]. In addition, stable preservation of cytochrome
P450 (CYP) dependent enzyme activities under serum-free conditions was shown, using a miniaturized
bioreactor variant [14,15].
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Figure 1. Schematic illustration of the three-dimensional (3D) multi-compartment hollow-fiber 
bioreactor technology. The bioreactor consists of three independent bundles of hollow fiber 
membranes interwoven in four layers. Each layer is composed of alternately arranged medium and 
gas capillaries. The two medium-carrying bundles (red and blue) are perfused in a counter-current 
way to enhance mass exchange. The third bundle (orange) serves for gas supply of the cells cultured 
between the capillaries. 
In this study, the metabolism and toxicity of the non-steroidal anti-inflammatory drug diclofenac 
were investigated. In humans, diclofenac is mainly hydroxylated by cytochrome P450 2C9 (CYP2C9) 
to form the oxidative metabolite 4′-OH-diclofenac [16]. In addition, diclofenac undergoes 
glucuronidation by uridine diphosphate (UDP)-glucuronosyltransferase-2B7 (UGT2B7) to form the 
unstable diclofenac-acyl-glucuronide, which can be further hydroxylated by CYP2C8 leading to  
4′-OH-diclofenac-acyl-glucuronide [17] (Figure 2). 
Diclofenac can cause idiosyncratic drug-induced liver injury (DILI), which is barely predictable 
in terms of manifestation and dose-dependency of effects [18]. In a study with 180 patients, diclofenac 
hepatotoxicity was observed in 85% of cases within six months of therapy [19]. Liver injury was 
characterized by clinical symptoms (e.g., jaundice) and/or changes in biochemical values (e.g., 
increased transaminase values) [19]. The mechanisms of diclofenac toxicity are not yet completely 
understood [20], although several hazards caused by its reactive adducts were identified including 
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In this study, the metabolism and toxicity of the non-steroidal anti-inflammatory drug
diclofenac were investigated. In humans, diclofenac is mainly hydroxylated by cytochrome P450 2C9
(CYP2C9) to form the oxidative metabolite 41-OH-diclofenac [16]. In addition, diclofenac undergoes
glucuronidation by uridine diphosphate (UDP)-glucuronosyltransferase-2B7 (UGT2B7) to form the
unstable diclofenac-acyl-glucuronide, which can be further hydroxylated by CYP2C8 leading to
41-OH-diclofenac-acyl-glucuronide [17] (Figure 2).
Diclofenac can cause idiosyncratic drug-induced liver injury (DILI), which is barely predictable
in terms of manifestation and dose-dependency of effects [18]. In a study with 180 patients,
diclofenac hepatotoxicity was observed in 85% of cases within six months of therapy [19]. Liver
injury was characterized by clinical symptoms (e.g., jaundice) and/or changes in biochemical values
(e.g., increased transaminase values) [19]. The mechanisms of diclofenac toxicity are not yet completely
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understood [20], although several hazards caused by its reactive adducts were identified including
oxidative stress [17], mitochondrial toxicity [20,21] as well as induction of an immune response via
hapten formation [22].
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i osphate (UDP)-glucuronosyltransferase-2B7 (UGT2B7) to form diclofenac-acyl-glu uronide, which
can be further hydroxylated by CYP2C8 to 41-OH-diclofena -acyl-glu uronide.
Hence, diclofenac was selected as a model drug to investigate the suitability of the bioreactor
technology for studies on hepatotoxicity. Two concentrations of diclofenac were used to identify a
potential dose-dependent toxic effect of the model drug with respect to the parameters determined.
The concentrations were chosen on the basis of studies by other groups performed in 2D or 3D culture
systems. Several studies showed a toxic effect of diclofenac in the range of 180–1000 µM upon 24 h of
exposure based on viability parameters such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay or lactate dehydrogenase (LDH) release [23–25]. Thus, one dose at the lower end
(300 µM bioreactors (300 µM BR)) and one dose at the higher end (1000 µM BR) of that range were
selected. Diclofenac was applied to primary human liver cells cultured in the bioreactors, and a possible
toxic effect of drug exposure was assessed in comparison to untreated control bioreactors (control
BR). This was performed by monitoring the metabolic activity of the cells over time with regard to
glucose and lactate metabolism and nitrogen elimination (urea and ammonia production). In addition,
the leakage of enzymes including alanine transaminase (ALT), aspartate transaminase (AST), LDH
and glutamate dehydrogenase (GLDH) was measured to detect potential cell damage caused by the
drug. The influence of diclofenac exposure on specific metabolism of the drug was analyzed by
measuring the formation of diclofenac products. Upon culture termination the reorganization and
differentiation state of the liver cells within the bioreactor was evaluated by means of histological
and immunohistochemical analysis. In order to identify potential effects of diclofenac application on
metabolic pathways and involved enzymes, the expression of genes assumed to be relevant in the
disposition and/or hepatotoxicity of diclofenac were analyzed by whole genome microarray analysis.
The design and time schedule of experiments is shown in Figure 3.
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bioreactors run with primary human liver cells.
2. Results
2.1. General etabolic Activity
The etabolic activities of liver cells in bioreactors exposed or non-exposed to diclofenac were
onitored throughout the entire cultivation period (Figure 4). After the initial adaptation phase
(Day 0–3), the glucose production rate (Figure 4A) decreased in all groups fro Day 3 until the end
of culture. hile the bioreactors exposed to 300 µ (300 µ BR) showed a comparable time-course
than the control group (control BR), bioreactors exposed to 1000 µ diclofenac (1000 µ BR) showed
a more distinct, though not significantly different, decrease in glucose production starting from Day 4.
The influence of drug application was more pronounced regarding lactate production rates (Figure 4B),
which showed a significant (p < 0.001) dose-dependent decrease in bioreactors exposed to diclofenac as
compared to the untreated control group. Release rates of the enzymes LDH and AST (Figure 4C,D) as
well as GLDH and ALT (Figure S1) showed similar kinetics in all groups until Day 7 with initial peaks
followed by a decrease to basal levels. Only LDH release was significantly lower in the 300 µM BR as
compared to the control BR (p < 0.05). From Day 7 on, however, values showed a stronger decrease
in the 1000 µM BR than in the other groups. Similarly, the production of urea (Figure 4E) showed a
distinct, although not significant, decrease from Day 7 in the 1000 µM BR, while both the control BR and
the 300 µM BR preserved stable values. The measured ammonia secretion rate showed an initial peak
in all groups, and returned to basal values on Day 4 (Figure 4F). At later time-points, both bioreactor
groups exposed to the drug differed significantly from the control runs. While the 300 µM BR showed
a similar course of ammonia release as the control BR, a drastic increase in ammonia concentration
was observed in the 1000 µM BR (p < 0.001).
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Due to the absence of available metabolite reference standards, the formation of diclofenac-acyl-
Figure 4. Time-course of clinical parameters in bioreact i ary human liver cells treated or
non-treat d with diclofenac. Rel ase respectively pr i 300 µM bioreactors (300 µM BR)
(blue) or 1000 µM bioreactors (1000 µM BR) (red) or in the no -treat d control bioreactors (control BR)
(black) were determin d before (from Day 0 until 3) and during diclofenac ap lication (fr 3
until 10): production rates of glucose (A) and lactate (B) were eas re as in icators for the overall
metabolic performance; lactate dehydrogenase (L , C) and aspartate transaminase (AST, D) were
determined as indicators of potential cell damage; and urea production (E) and ammonia release (F) as
parameters for nitrogen metabolism. Values were normalized to 106 inoculated cells. The influence
of the drug dose (Day 3–10) on the metabolic activity of the cells in comparison to the control was
analyzed by means of one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test
and significant changes (* = p < 0.05, *** = p < 0.001) are indicated in the graphs (n = 3, mean ˘ SEM).
2.2. Formation of Diclofenac Metabolites
Samples for determining the parent drug diclofenac and its metabolites were taken at defined
time-points from drug-treated bioreactors in accordance to the sample schedule (see Figure 3).
As shown in Figure 5A, an initial diclofenac concentration of 56.3 ˘ 2.5 µM in the 300 µM BR
respectively 128.4 ˘ 18.7 µM in the 1000 µM BR was measured directly after application to the
system (Day 3, 0 h), i.e., in average only 16% of the desired concentration was achieved.
During the first six hours of exposure the concentrati f icl fenac decreased rapidly in both
groups (Figure 5A). In the 300 µM BR a steady state i i et een 24 and 96 h of exposure
foll wed by a slow increase. In contrast, a significant i c ar regre sion of R2 = 0.430
(p < 0.05) was observed for the 100 µM BR. The drug was rapidly eliminated in both groups within the
firs fou hours with an initial elimination r te of 11.7 ˘ 1.2 (300 µM BR) or 31.5 ˘ 5.2 nmol/h/106 cells
(1000 µM BR), followed by a stable elimination rate of 4.35 ˘ 0.37 nmol/h/106 cells when applying the
lower dose or 12.2 ˘ 0.8 nmol/h/106 cells in the 1000 µM BR fro 24 h to the end of drug exposure
on Day 10 (Figure 5B). All investigated diclofenac metabolites could be detected. The concentration
of 41-OH-diclofenac (Figure 5C) was increased initially in all bioreactors with maximum values of
8.56 ˘ 3.39 µM for the 300 µM BR and 20.3 ˘ 8.0 µM for the higher dose (1000 µM BR) after 48 h,
which was followed by an significant decrease in the concentration in the 1000 µM BR (R2 = 0.409,
p < 0.01). As shown in Figure 5D, the formation rate of 41-OH-diclofenac was lower in the 300 µM
BR with a maximum formation rate of 0.46 ˘ 0.14 nmol/h/106 cells after two hours as compared to
the 1000 µM BR with 0.62 ˘ 0.23 nmol/h/106 cells. Afterwards, a significant decrease was observed
in both groups, (300 µM BR: R2 = 0.274, p < 0.05; 1000 µM BR: R2 = 0.470, p < 0.001) reaching similar
values after 120 h. Due to the absence of available metabolite reference standards, the formation of
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diclofenac-acyl-glucuronide (Figure 5E) was determined by mass spectrometry (MS) area units. These
showed an increase to a maximum of 78.4 ˘ 34.1 ˆ 103 relative MS area units at 48 h in the 300 µM BR
and maintained a stable level of approximately 67.1 ˘ 41.2 ˆ 103 relative MS area units afterwards.
In contrast, the maximal formation of this metabolite in the higher dose bioreactors was already
measured at 24 h after starting with diclofenac exposure (56.9 ˘ 37.1 ˆ 103 relative MS area units).
From Day 4 (24 h), a steep, significant decrease towards nearly zero on Day 8 (120 h) could be detected in
the 1000 µM BR (R2 = 0.332, p < 0.01). The formation of 41-OH-diclofenac-acyl-glucuronide (Figure 5F)
showed a comparable time-course in both groups with a maximum amount of 26.2 ˘ 18.6 ˆ 103
relative MS area units for the 300 µM BR respectively 11.2 ˘ 9.3 ˆ 103 relative MS area units for the
1000 µM BR at Day 4 (24 h) followed by a decrease, which showed statistical significance only in the
1000 µM BR (R2 = 0.237, p < 0.05).
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Figure 5. Conversion of diclofenac to specific metabolites in bioreactors with primary human liver
cells: diclofenac concentrations (A); diclofenac decrease rates (B); 41-OH-diclofenac concentrations
(C); and 41-OH-diclofenac formation rates (D) as well as mass spectrometry (MS) area units of
diclofenac-acyl-glucuronide (E) and 41-OH-diclofenac-acyl-glucuronide (F) were determined in 300 µM
bioreactors (300 µM BR) (blue) or 1000 µM bioreactors (1000 µM BR) (red) from Day 3 to 10 of
culture. Values were normalized to 106 inoculated cells. The course over time (Day 3–10) of diclofenac
metabolism was analyzed by linear regression analysis and significant changes (* = p < 0.05, ** = p < 0.01,
*** = p < 0.001) as well as respective regression coefficients are indicated in the graphs. (n = 3,
mean ˘ SEM).
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2.3. Cell Morphology and Reorganization in the Bioreactor
The morphologic appearance and reorganization state of hepatocytes and non-parenchymal liver
cells within the bioreactor was investigated after 10 days of cultivation with or without diclofenac
exposure by means of histological and immunohistochemical analysis (Figure 6).
The hematoxylin and eosin staining (Figure 6A–C) demonstrated a compact network of cell
aggregates within the control BR group (Figure 6A), while diclofenac exposure resulted in partial
disruption of aggregates, especially in the 1000 µM BR, which showed a high amount of disintegrated
cells (Figure 6C). Hepatocytes characterized by the liver epithelial marker cytokeratin 18 (CK18)
and non-parenchymal cells showing vimentin immunoreactivity could be observed in all cultures
(Figure 6D–F). The non-parenchymal cells were integrated in the parenchymal aggregates and formed
strand-like cell linings in both the control BR and the 300 µM BR (Figure 6D,E), while in the 1000 µM BR
the cells appeared less organized. All cultures showed positive staining of the diclofenac metabolizing
CYP isoform CYP2C9 located in the cytoplasm of the hepatocytes (Figure 6G–I). In addition, the biliary
transporter breast cancer resistance protein (BCRP) was clearly visible in plasma membranes of the
pHH (Figure 6G–I). Although all markers under investigation could be detected in all bioreactors, the
cell density and the reorganization state of the cells were lower in the 1000 µM BR group.
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Figure 6. Histological and immunohistochemical analysis of primary human liver cells cultured in
bioreactors with or without diclofenac application: cell material from untreated control bioreactors
(control BR) (A,D,G); 300 µM bioreactors (300 µM BR) (B,E,H); or 10 0 µM bioreactors (1000 µM BR)
(C,F,I) was investigated at the end of the experimental phase on Day 10 of culture. The upper row
(A–C) shows hematoxylin and eosin staining of cultures; the middle row (D–F) shows CK18 (green)
and vimentin (red); and the lower row (G–I) shows BCRP (green) and CYP2C9 (red) immunoreactivity.
Counterstaining of nuclei is shown in blue (scale bar = 50 µM).
2.4. Analysis of Transcriptomic Data upo Drug Application
At the end of the experiment, total RNA was isolated and whole genome microarray analysis
was performed to study specific gene expression profiles. Initial modeling was performed using the
donor and do e group as fixed factors to t st for possible donor effects. Only genes with an adjusted
p-value < 0.05 were considered significant. This analysis highlighted only a modest number of genes,
which differed between donors across the tested dose range, i.e., 11 genes or 0.06% of analyzed genes
(Table S1). Relative average expression levels of selected basal hepatocyte function markers, and
relevant drug metabolizing enzymes and transporters involved in the disposition and excretion of
diclofenac are shown in Figure 7. The hepatic phenotype of primary human liver cells, assessed by
expression levels of liver-specific marker genes over time, was well maintained in the system for
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the entire duration of the experiment and displayed good correlation with the expression levels in
freshly isolated hepatocytes. Similarly, expression levels of drug metabolizing enzymes known to
be important in the metabolism of diclofenac (CYP2C9, CYP3A4, UGT2B7, ATP-binding cassette B1
(ABCB1); ATP-binding cassette C2 (ABCC2), and ATP-binding cassette G2 (ABCG2)) showed a high
and stable expression for the entire duration of the experiment, although a pronounced decrease was
observed for CYP2C8 and CYP2C19 from Day 0 to 10 after cell inoculation (Figure 7).
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Figure 7. Microarray analysis of primary human liver cells cultured in bioreactors with or without
diclofenac exposure. The graph shows average intensities of key genes involved in diclofenac
metabolism and diclofenac-mediated toxicity determined in freshly isolated liver cells (Day 0) or
cells cultured in bioreactors until Day 10 without diclofenac (control bioreactors (control BR)) or with
diclofe ac (300 µM bioreactors (300 µM BR)) or 1000 µM bioreactors (1000 µM BR)). Measured genes
include albumin (ALB), α-1-anti rypsin (A1AT), transthyreti (TTR), apolipo r tein C-I (APOC1),
β-2-microglobulin (B2M), selected cytochrome P450 (CYP) isoenzymes, uridine diphosphate (UDP)
glucuronosyltransferase 2B7 (UGT2B7), ATP-binding cassette B1 (ABCB1), ATP-binding cassette C2
(ABCC2), and ATP-binding cassette G2 (ABCG2) (control BR (n = 6), 300 µM BR (n = 4), 1000 µM BR
(n = 3)).
Based on th limited inter-donor effects on overal transcription levels, a simplifi model was
applied to test the effect of diclofenac exposure by using the dose group as a single fixed factor to
identify genes differentially affected between the samples tested at a specific dose compared to the
control BR. Exposure of the liver cells to diclofenac at concentrations of 300 and 1000 µM resulted in
gene expression changes in 281 genes (i.e., 1.52%), and 8598 genes (46.38%), respectively, as compared
with the untreated control BR (Figure 8A,B). Whereas transcription in the 300 µM BR was primarily
downre ulated (188 out f 281 gene downregulated—i.e., 66.90%), in the 1000 µM BR approximately
equivalent numbers of upr gulat d (4416 out of 8598 genes—i.e., 51.36%) and downregulated genes
(4182 out of 8598 genes—i.e., 48.64%) were found. Nevertheless, transcriptional downregulation was
significantly more pronounced, as evidenced by the strong relative-fold downregulation of the 50 most
significantly affected genes in the 1000 µM BR group.
Of note, 246 out of 281 genes that differed significantly between the 300 µM BR and the control
BR displayed a linear dose-response relationship resulting in an equivalent or greater relative fold
change in expression in the 1000 µM BR (Figure 8A), underscoring the p ssibility of shared regulation
pathways. An ov rview of the most significantly aff ct d genes in t e 300 µM BR and the 1000 µM
BR is shown in Tables S2 and S3, respectively. To further study the tentative biological effects of
diclofenac-induced transcriptional changes, a pathway analysis was performed based on the Gene
Ontology (GO) database. In the 300 µM BR group (Table 1), transcriptional changes induced by
diclofenac are mainly linked to various immune processes, including chemokine-related chemotaxis
(GO:0002687), chemokine receptor binding (GO:0042379), protein activation cascades (GO:0072376)
and regulation of leukocyte migration (GO:0002687). Contrastingly, in the 1000 µM BR (Table 2),
the strongest effects on gene transcription were observed in pathways related to basal cell functions
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including regulation of cellular amino acid metabolic processes (GO:0006521), G1 DNA damage
checkpoint proteins (GO:0044783), proteasome complex proteins (GO:0000502), oxidoreductase
complex proteins (GO:1990204), and respiratory chain proteins (GO:0070469).
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Figure 8. Volcano plot representing the differential expression of all measured genes after exposure
to diclofenac: the transcriptional effects of treatment in 300 µM bioreactors (300 µM BR) (A) or
1000 µM bioreactors (1000 µM BR) (B). The x- and y-axes represent the magnitude and the significance,
respectively, of the transcriptional effect per gene (control bioreactors (control BR) (n = 4), 300 µM BR
(n = 4), 1000 µM BR (n = 3), LogFC: Log2 fold change in expression as compared to control BR).
Table 1. Gene Ontology (GO) gene sets most strongly affected upon treatment with a low dose of
diclofenac (300 µM bioreactors).
Rank ID Size p-Value Description Parent
Gene Ontology Biological Processes
1 GO:0072376 67 90 6.0 ˆ 10´33 Protein activation cascade
2 GO:0006956 47 (69) 1.8 ˆ 10´31 Complement activation 1
3 GO:0016 64 94 (119) 9.8 ˆ 10´29 Immunog obulin mediated immune response
4 GO:0002455 43 (67) 1.0 ˆ 10´27 Humoral immune response mediated bycirculating immunoglobulin 3
5 GO:0019724 97 (122) 4.9 ˆ 10´27 B cell mediated immunity 3
6 GO:0002576 83 (87) 1.4 ˆ 10´26 Platelet degranulation
7 GO:0002687 89 (90) 3.5 ˆ 10´26 Positive regulation of leukocyte migration
8 GO:00 6958 1 52 2.0 ˆ 10´22 Com leme t activation, classical pathway 1, 2, 3, 4, 5
9 GO:0002688 79 (83) 2.7 ˆ 10´21 Regulation of leukocyte chemotaxis
10 GO:0002690 68 (69) 2.8 ˆ 10´18 Positive regulation of leukocyte chemotaxis 7, 9
Gene Ontology Cellular Component
1 GO:0032994 37 (40) 8.7 ˆ 10´25 Protein-lipid complex
2 GO:0034358 35 (38) 1.8 ˆ 10´24 Plasma lipoprotein particle 1
3 GO:0042613 12 (16) 4.6 ˆ 10´24 MHC class II protein complex
4 GO:0042611 22 (27) 1.6 ˆ 10´20 MHC protein complex 3
5 GO:0031983 73 (82) 1.1 ˆ 10´19 Vesicle lumen
6 GO:0060205 72 (81) 2.4 ˆ 10´19 Cytoplasmic membrane-bounded vesicle lumen 5
7 GO:0030134 48 (52) 6.7 ˆ 10´17 ER to Golgi transport vesicle
8 GO:0012507 38 (42) 1.6 ˆ 10´15 ER to Golgi transport vesicle membrane 7
9 GO:0034364 23 (26) 1.0 ˆ 10´14 High-density lipoprotein particle 1, 2
10 GO:0031091 60 (63) 1.3 ˆ 10´12 Platelet α granule
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Table 1. Cont.
Rank GO ID Size p-Value Description Parent
Gene Ontology Molecular Functions
1 GO:0042379 54 (58) 2.8 ˆ 10´9 Chemokine receptor binding
2 GO:0008009 43 (47) 1.3 ˆ 10´8 Chemokine activity 1
3 GO:0030170 53 (56) 5.3 ˆ 10´7 Pyridoxal phosphate binding
4 GO:0003823 76 (107) 2.0 ˆ 10´6 Antigen binding
5 GO:0045236 17 (17) 9.7 ˆ 10´6 CXCR chemokine receptor binding 1, 2
6 GO:0023026 15 (16) 2.6 ˆ 10´5 MHC class II protein complex binding 4
7 GO:0060228 6 (6) 3.1 ˆ 10´5 Phosphatidylcholine-sterolO-acyltransferaseactivator activity
8 GO:0031210 15 (16) 4.7 ˆ 10´5 Phosphatidylcholine binding
9 GO:0019864 8 (12) 1.1 ˆ 10´4 IgG binding
10 GO:0023023 17 (19) 1.6 ˆ 10´4 MHC protein complex binding 4, 6
Table 2. Gene Ontology (GO) gene sets most strongly affected upon treatment with a high dose of
diclofenac (1000 µM bioreactors).
Rank GO ID Size p-Value Description Parent
Gene Ontology Biological Processes
1 GO:0042590 74 (79) 1.2 ˆ 10´46 Antigen processing and presentation of exogenous peptideantigen via MHC class I
2 GO:0002479 70 (75) 2.1 ˆ 10´36 Antigen processing and presentation of exogenous peptideantigen via MHC class I, TAP-dependent 1
3 GO:0006521 59 (62) 1.0 ˆ 10´31 Regulation of cellular amino acid metabolic process
4 GO:0033238 79 (82) 2.9 ˆ 10´26 Regulation of cellular amine metabolic process
5 GO:0002576 83 (87) 8.9 ˆ 10´19 Platelet degranulation
6 GO:0044783 75 (77) 3.9 ˆ 10´17 G1 DNA damage check point
7 GO:0051437 68 (72) 6.7 ˆ 10´17 Positive regulation of ubiquitin-protein ligase activity
8 GO:0051351 86 (94) 1.4 ˆ 10´16 Positive regulation of ligase activity
9 GO:0051436 63 (67) 2.1 ˆ 10´16 Negative regulation of ubiquitin-protein ligase activity
10 GO:0051443 81 (89) 3.0 ˆ 10´16 Positive regulation of ubiquitin-protein transferase activity 8
Gene Ontology Cellular Component
1 GO:0000502 63 (66) 3.6 ˆ 10´25 Proteasome complex
2 GO:1990204 78 (83) 2.6 ˆ 10´18 Oxidoreductase complex
3 GO:0043202 72 (73) 2.5 ˆ 10´16 Lysosomal lumen
4 GO:0005775 73 (77) 1.4 ˆ 10´15 Vacuolar lumen 3
5 GO:0031091 60 (63) 3.1 ˆ 10´15 Platelet α granule
6 GO:0070469 65 (72) 3.1 ˆ 10´15 Respiratory chain
7 GO:0005746 59 (65) 9.6 ˆ 10´13 Mitochondrial respiratory chain 6
8 GO:0022624 22 (24) 3.9 ˆ 10´12 Proteasome accessory complex 1
9 GO:0031902 93 (99) 3.1 ˆ 10´11 Late endosome membrane
10 GO:0005839 20 (20) 1.6 ˆ 10´10 Proteasome core complex 1
Gene Ontology Molecular Functions
1 GO:0009055 89 (99) 8.2 ˆ 10´21 Electron carrier activity
2 GO:0003743 48 (52) 1.1 ˆ 10´14 Translation initiation factor activity
3 GO:0016651 87 (95) 9.7 ˆ 10´14 Oxidoreductase activity, acting on NAD(P)H
4 GO:0016655 49 (53) 1.6 ˆ 10´12 Oxidoreductase activity, acting on NAD(P)H, quinon orsimilar compound as acceptor 3
5 GO:0008135 75 (83) 2.9 ˆ 10´11 Translation factor activity, nucleic acid binding
6 GO:0004298 21 (21) 4.3 ˆ 10´8 Threonine-type endopeptidase activity
7 GO:0070003 21 (21) 4.3 ˆ 10´8 Threonine-type peptidase activity 6
8 GO:0016830 45 (47) 1.1 ˆ 10´6 Carbon-carbon lyase activity
9 GO:0003954 36 (39) 2.4 ˆ 10´6 NADH dehydrogenase activity 3, 4
10 GO:0008137 36 (39) 2.4 ˆ 10´6 NADH dehydrogenase (ubiquinone) activity 3, 4, 9
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With regard to decreased urea production in the 1000 µM BR, a strong negative regulation for
ornithine transcarbamoylase (OTC), mitochondrial carbamoyl-phosphate synthase 1 (CPS1), arginase 1
(ARG1), and argininosuccinate lyase (ASL) could be detected in the 1000 µM BR. Further, significant
effects on the expression of cellular sensors of chemically induced oxidative and electrophilic stress
nuclear factor (erythroid-derived 2)-like 2/kelch-like ECH-associated protein 1 (NRF2/KEAP1) as well
as activating transcription factor 3 (ATF3) and growth differentiation factor 15 (GDF15) was observed
in the 1000 µM BR, whereas these genes were not affected in bioreactors exposed to the lower dose of
diclofenac. A complete overview of the magnitude of transcriptional changes expressed as the relative
fold-changes in gene expression of individual genes is provided in the Table S4.
3. Discussion
Xenobiotics, including drugs, are typically biotransformed in hepatocytes to enhance their renal
or biliary excretion. However, the parental drug itself and the formed potential toxic metabolites
(i.e., biotoxification) can both lead to hepatotoxicity. Primary human liver cells cultured in a dynamic
3D bioreactor system could be useful to investigate hepatic drug effects in vitro with high predictivity.
The data from untreated bioreactors (control BR) indicate a stable performance of the hepatocytes
subsequent to an adaption phase of three days. This is in consistence with previous studies showing
prolonged preservation of hepatocyte functionality in the 3D bioreactor as compared to 2D cultures [14].
A beneficial effect of co-cultivating pHH and non-parenchymal cells (Kupffer and endothelial cells) was
also shown in a 3D human liver tissue model [26], emphasizing the importance of the microarchitecture
of the liver to maintain cell viability.
To demonstrate the suitability of the bioreactor system for hepatotoxicity studies, diclofenac
was selected as a model drug. The drug was applied at two different doses (300 or 1000 µM) over
seven days to the system. Previous toxicity assays performed in conventional 2D cultures showed
that these concentrations caused a rapid cell death [23,24]. In line with these previous reports, the
present study shows a dose-dependent toxic effect of diclofenac based on combined metabolic data,
immunohistochemical and gene expression analysis.
Glucose production and lactate production rates determined in the cultures as parameters of
energy metabolism showed distinct differences in the cell response to diclofenac application. Whereas
the time-course of glucose production rates over the culture time was similar in all bioreactors, with
slightly lower values in the 1000 µM BR, lactate production rates showed a clear dose-dependent
influence of drug exposure. In contrast to the control BR, which showed stable lactate production
rates throughout the culture period, a significant decrease after diclofenac infusion was detected
in both drug-treated groups, with reduction of lactate production by approx. 50% in the 300 µM
BR, and nearly complete loss of lactate production in the 1000 µM BR. This might be caused by the
alterations of mitochondrial functions induced by diclofenac [27]. The value of these basal metabolism
parameters was previously confirmed by Prill et al. [28], who demonstrated the suitability of continuous
glucose and lactate monitoring as an evaluation parameter for high-throughput microbioreactors.
An additional option for measuring metabolic activities of the cells in the bioreactor can be seen in
resazurin-based cell viability assays, like CellTiter-Blue® or alamarBlue®. It was previously shown
that the resazurin assay can be repeatedly applied to bioreactor cultures with HepG2 or pHH [29].
However, other studies showed a toxic effect of resazurin upon long-term exposure [30,31], which
could impair the effect of diclofenac exposure.
Further, a panel of liver enzymes (AST, ALT, GLDH and LDH) was measured. These enzymes are
released upon membrane leakage in case of cell damage and their elevation in plasma is characteristic
for liver injury [32,33]. In this study no distinct effects on liver enzyme release of drug application
was observed. After a high initial release the rates decreased and reached stable values on a basal
level from Day 5 onwards. This is in consistence with results from Wang et al. [34], who found an
absence of enzyme release in rat hepatocytes treated with diclofenac in 2D cultures. The high release
rates during the initial culture phase can most likely be attributed to cell stress as a consequence
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resulting from cell isolation. Liberation of large amounts of enzymes can result in an exhaustion of
enzyme stores preventing further increase upon drug application. Only LDH release was significantly
different between the 300 µM BR and the control BR, with lower levels for the 300 µM BR. This can be
interpreted as a sign of a stabilizing metabolism with production of LDH under control conditions.
Active nitrogen elimination by the hepatocytes via deamination is indicated by stable urea
production rates in the control BR and in the 300 µM BR. In contrast, urea production decreased over
time in the 1000 µM BR demonstrating the harmful effect on cell metabolism of higher concentrations
of diclofenac. This is in accordance with findings of Borlak et al. [35], who recently suggested urea
as a robust marker to predict hepatocellular stress during in vitro preclinical studies. The disturbed
detoxification of nitrogen is confirmed by the significant increase of the ammonia release observed in
the 1000 µM BR with values elevated by five-fold compared to the control BR. The accumulation of the
toxic base ammonia can further contribute to cell death upon toxic drug exposure. Thus, the results
from biochemical parameters indicate that lactate production rate as a marker for energy metabolism
and ammonia release in combination with the urea production rate as markers for nitrogen metabolism
provide useful markers for evaluation of the cell response to toxic drug exposure.
Single application of diclofenac at a therapeutic dose of 75 mg leads to a maximum plasma
concentration of 6.4 µM diclofenac [36]. In clinical reports hepatotoxicity of diclofenac was observed
in some patients at a daily dose in the range of 75–200 mg applied over weeks to months [37–39].
In vitro concentrations tested with respect to hepatotoxicity range between 10 and 1000 µM, with a
toxic effect of diclofenac being detected at concentrations between 180 and 1000 µM upon 24 h of
exposure [23–26]. Messner et al. [26] reported an IC50 value of 178.6 µM after diclofenac treatment of
liver microtissues over 14 days, while Bort et al. [23] and Lauer et al. [25] observed higher values, with
an IC50 of 331 ˘ 7 µM and a TC50 of 222 ˘ 142 µM, respectively, which is in the range of the dose of
300 µM used in the present study. However, the direct comparison of data from different studies is
difficult due to differences in the culture system, culture condition and assays applied for assessment
of toxicity. In addition, potential adsorption processes to culture materials may influence the free
concentration of drugs applied. This assumption is supported by the fact that the free diclofenac levels
measured directly after application to the bioreactor system (Day 3, 0 h) amounted only to 15% of the
expected concentration. Thus, the results indicate a significant loss of the substance in the system,
probably due to drug adsorption to the capillary membranes of the bioreactor and/or binding to
membrane-bound and soluble proteins [17].
After an initial decrease of the free diclofenac concentration in both bioreactors the free
diclofenac concentration increased rapidly in the 1000 µM BR towards the starting concentration.
In contrast, nearly constant conversion of diclofenac was observed in the 300 µM BR until the end of
culture, amounting to around 60% of the initial drug concentration. The finding that the observed
increase is more pronounced in the 1000 µM BR than in the 300 µM BR indicates an impaired cell
metabolism in association with a decreased conversion of diclofenac, in addition to potential adsorption
processes. While all metabolites under investigation could be detected in the culture perfusates,
the time-course of metabolites showed a different behavior in 300 or 1000 µM BR. Time-courses
of 41-OH-diclofenac indicate that pHH in bioreactors actively metabolized diclofenac via CYP2C9
dependent oxidation, since a clear dose-dependent formation rate was detected with much higher
values in the 1000 µM BR. This finding is consistent with observed metabolite profiles of excretory
pathways in humans, indicating that the in vivo clearance in humans is with around 50% mainly based
on the oxidative metabolism [16]. The primary metabolite 41-OH-diclofenac can be further oxidized
resulting in an electrophilic quinone imine, which may influence the redox cycling of the cells, produce
oxidative stress and can covalently bind to various molecules because of its thiol reactivity [17]. As a
consequence, disruption of the balance of cell metabolism can occur. Thus, the continuous decrease of
41-OH-diclofenac formation observed in the 1000 µM BR may partly be caused by toxic effects of the
secondary quinone imine product. Since covalent protein binding was not assessed in the current study,
it cannot be confirmed that this proposed mechanism was indeed a contributing factor to the observed
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toxic effects of diclofenac in the bioreactor system. The formation of diclofenac-acyl-glucuronides
and 41-OH-diclofenac-acyl-glucuronides catalyzed by UGT2B7 and CYP2C8, respectively, showed
a similar relatively stable time-course at the lower dose application, and a distinct decrease in the
1000 µM BR, confirming the toxic effect of high concentrations of diclofenac and its metabolites on
the activities of drug metabolizing enzymes. Due to their labile ester bond acyl-glucuronides are
capable of covalent binding to proteins, reducing their function [40] or even result in immune-mediated
destruction of hepatocytes [41]. The high standard deviations especially in the results of diclofenac
biotransformation could be potentially resulting from inter-donor variances in enzyme activities,
e.g., CYP2C9 activity [42]. While such variances make the statistical evaluation of data from pHH
difficult, they also provide the option to reproduce the range of functions and enzyme expression in
different patients [2]. In contrast, hepatic cell lines like HepG2 display a reduced expression of CYP
enzymes [43], which may impair the hepatotoxic response as previously shown by Rodrigues et al. [44].
Histological and immunohistochemical studies performed after 10 days of cultivation showed
tissue-like aggregates of pHH with strand-like cell linings of non-parenchymal cells, confirming
supportive conditions for liver cell reorganization in the bioreactor system. In addition, CYP2C9,
which is mainly responsible for diclofenac metabolism [17], and also the transporter of the parent drug,
namely BCRP [45], were well-preserved in bioreactors after cultivation. This physiological in vitro
representation of in vivo liver tissue with a heterogeneous cell population made of parenchymal and
non-parenchymal cells is important for clinical-relevant hepatotoxicity testing. It has been shown that
the activation of inflammatory cells can enhance DILI [46]. In another study, a protective effect of cell
populations like Kupffer cells against drug exposure was observed [47].
Stable preservation of hepatic markers in the bioreactor system was confirmed by microarray
analyses showing that the hepatic phenotype of donor cells, assessed by expression levels of
liver-specific marker genes (including albumin, α-1-antitrypsin, transthyretin, apolipoprotein C-I
and β-2-microglobulin), was well-maintained in the system for the entire duration of the experiment
and correlated to the expression levels in freshly isolated liver cells, in accordance with previous
studies [14,15]. This is a major advantage over conventional 2D cultivation where a rapid and marked
decrease of gene expression encoding for CYP was observed as compared to those expressed in freshly
isolated human hepatocytes [4]. To further identify differential effects of diclofenac dose on overall
cell function in the bioreactor system, a transcriptomics analysis was performed. Although distinct
differences could be detected between control bioreactors and bioreactors exposed to increasing doses
of diclofenac, it should be noted, however, that the current study may lack a bona fide time-dose
response relation to allow lege artis delineation of potential mechanistic pathways underlying
diclofenac toxicity in hepatocytes, and thus these data should be interpreted with caution. After
seven days of continuous exposure to diclofenac, cells in the 300 µM BR displayed transcriptional
changes in various immune processes, emphasizing the possible role of immune-mediated toxicity
in the development of diclofenac induced liver injury [17]. In contrast, in the 1000 µM BR a broad
range of basal cell function pathways displayed strong dysregulation (including G1 DNA damage
checkpoint proteins, mitochondrial respiratory chain enzymes, and proteasome function), which likely
reflects the overall toxic insult of long term exposure. Although these observed changes may likely
not be relevant readouts for the initiating effects of diclofenac during initial exposure, the strong
observed dose-dependent changes in the canonical toxicity pathways associated with diclofenac do
indeed support a faithful representation of previously published pathways involved in the perfused
3D bioreactors [48].
These observations are also corroborated by Zhang et al. [49] who recently reported the use of the
TG-GATES database to identify a set of four marker genes (early growth response protein 1 (EGR1),
ATF3, GDF15 and fibroblast growth factor 21 (FGF21)) with the potential to serve as biomarkers for
prediction of liver toxicity. In line with Zhang et al. [48,50], a pronounced transcriptional effect for
ATF3 and GDF15 was observed in the 1000 µM BR, whereas these genes were not changed in the
300 µM group. Similarly, a distinct change in the expression of NRF2/KEAP1 was detected, which is in
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line with studies on HepG2 cells showing that oxidative stress and cytokine signaling based on the
activation of the transcription factor NRF2 arise as a result of adverse drug reaction.
4. Materials and Methods
4.1. Bioreactor Technology
The used multi-compartment bioreactor consists of three independent but interwoven hollow-fiber
capillary systems: two counter-currently perfused medium compartments and one gas compartment
that serves for decentralized oxygenation (Figure 1). The cells are located in the fourth compartment,
the space formed by the capillary network. A detailed description of the technology can be found
elsewhere [15]. In modification of the previously described bioreactor model the bioreactor used in this
study contains four capillary layers instead of two layers resulting in a cell compartment volume of
0.5 mL. After connection to a sterile tubing system, the bioreactors were operated in a perfusion device
enabling the regulation of medium flow rates and temperature. An integrated electronically operated
gas-mixing unit was used for the control of air and CO2-flow rates. Bioreactors, tubing systems and
perfusion devices were manufactured by Stem Cell Systems, Berlin, Germany.
4.2. Isolation of Primary Human Liver Cells
Primary human liver cells were isolated from resected liver tissue from partial hepatectomies
with written consent of the patients. The study was conducted in accordance with the Declaration of
Helsinki, and the protocol was approved by the Ethics Committee of Charité—Universitätsmedizin
Berlin (approval dated 11 April 2013; Project identification code: European Union’s Seventh Framework
Programme (FP7/2007-2013EU)). Cell isolation was performed using a two-step collagenase perfusion
technique [51] with modifications as described by Pfeiffer et al. [52]. Three cell preparations from
individual donors with a viability between 79% and 84% were included in this study.
4.3. 3D Culture of Primary Human Liver Cells
At least 24 h prior to cell inoculation the bioreactors and connected tubing systems (total system
volume: 14 mL) were filled with liver cell culture medium (Heparmed Vito143, Biochrom, Berlin,
Germany). The culture medium was supplemented with 20 IU/L insulin, 5 mg/L transferrin, 3 mg/L
glucagon, 100,000 U/L penicillin, and 100 mg/L streptomycin (all Biochrom) before use. A number
of 4 ˆ 107 total cells from each cell preparation were suspended in up to 4 mL culture medium and
inoculated into three parallel bioreactors. The perfusion parameters were set to 3 mL/min for the
recirculation flow rate, 0.5 mL/h for the fresh medium flow rate and 5 mL/min for the gas flow rate.
The pH value was measured on a daily basis or more frequently, if needed, with a clinical analyzer
(ABL 700, Radiometer, Copenhagen, Denmark) and kept between 7.35 and 7.45 by varying the amount
of CO2 in the range of 4% and 5.5%. The bioreactors were maintained at 37 ˝C over 10 days. On Day
3 of culture, the drug-free culture medium was exchanged with culture medium containing 300 µM
(300 µM BR) or 1000 µM (1000 µM BR) diclofenac sodium salt (Sigma-Aldrich, St. Louis, MO, USA).
The perfusion with diclofenac-containing medium was continued until the end of the culture period
on Day 10. The third bioreactor (control BR), a non-treated control, was flushed as well and run in
parallel without continuous diclofenac exposure.
4.4. Analysis of Clinical Parameters
For determination of the metabolic activity of the cells, samples from culture perfusates
(for measurement of glucose, lactate, urea and enzyme release) or from the medium outlet (for ammonia
measurement) were taken daily according to the time schedule shown in Figure 2. Measurements of
glucose and lactate concentrations were performed with a blood gas analyzer (ABL 700, Radiometer).
Urea and ammonia concentrations, as well as enzyme activities of AST, ALT, LDH and GLDH were
determined with an automated clinical chemistry analyzer (Cobas® 8000, Roche Diagnostics GmbH,
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Mannheim, Germany). The calculation of daily production or release rates was performed on the basis
of the total system volume and feed rate as described by Hoffmann et al. [14].
4.5. Analysis of Diclofenac and Its Metabolites
Following diclofenac application on culture Day 3, samples from the culture perfusates were
taken at 0, 1, 2, 4, 6, 24, 48, 72, 96, 120, 144 and 168 h according to the time schedule shown in
Figure 3 for quantification of the parent drug (diclofenac) and formed metabolites (41-OH-diclofenac,
diclofenac-acyl-glucuronide, and 41-OH-diclofenac-acyl-glucuronide) by liquid chromatography-mass
spectrometry/mass spectrometry (LC-MS/MS). Medium probes were mixed in a 1:1 ratio (v:v) either
with dimethyl sulfoxide ((DMSO), Carl Roth, Karlsruhe, Germany) for analysis of 41-OH-diclofenac or
with DMSO containing 10% formic acid (Sigma-Aldrich) for analysis of acyl-glucuronide. Subsequently,
samples were snap-frozen and stored at ´80 ˝C until further analysis. Samples were injected using
acetonitrile and ultrapure water as organic and aqueous mobile phases, respectively. Both mobile
phases were fortified with 0.1% (v:v) formic acid. Separation was carried out using an Acquity UPLC
column (BEH C18 (1.7 µm) 50 ˆ 2.1 mm ID, column temperature = 50 ˝C) and eluted fractions were
directly passed through a Xevo TQ-S tandem mass spectrometer (Waters Corp., Milford, MA, USA)
operated in negative electrospray ionization mode. Acquired data were processed with Thermo
Xcaliber software (Thermo Scientific, Waltham, MA, USA).
4.6. Histology and Immunohistochemistry
Upon termination of bioreactor cultures on Day 10 of culture, bioreactors were opened and
sections of the capillary bed containing the cell material were taken. Samples were fixed in 4% formalin
solution (Herbeta Arzneimittel, Berlin, Germany), dehydrated and embedded in paraffin. Slides of
2.5-µM thickness were deparaffinized and rehydrated. For histological analysis slides were shortly
rinsed with distilled water, incubated for 20 min with Harris’ hematoxylin solution (Sigma-Aldrich),
rinsed 3 min under running tap water and incubated for 2 min in eosin solution (Carl Roth). Finally
slides were dehydrated and fixed. For immunohistochemistry, initial antigen retrieval was performed
by incubation with 0.1 M citrate buffer in a pressure cooker for 15 min, followed by incubation of slides
with blocking buffer (phosphate buffered saline (PBS; Life Technologies, Carlsbad, CA, USA) with 2%
fetal calf serum (PAA, Pasching, Austria) and 2.5% bovine serum albumin (Sigma-Aldrich) for 1 h at
room temperature. Subsequently the sections were incubated for 1 h with primary antibodies (1:100
dilution), followed by 1 h incubation with the secondary antibodies (1:1000 dilution). Monoclonal
mouse antibodies against CK18 (ab668, Abcam, Cambridge, UK) or BCRP (ab3380, Abcam), and
polyclonal rabbit antibodies against vimentin (sc-5565, Santa Cruz, Santa Cruz, CA, USA) or CYP2C9
(PAP091, Nosan, Yokohama, Japan) were used as primary antibodies. As secondary antibodies,
fluorochrome-coupled anti-mouse IgG 488 (A11029; Life Technologies) and anti-rabbit IgG 594 (A11037;
Life Technologies) were used. Counterstaining of nuclei was performed using bisbenzimide H 33342
trihydrochloride ((Hoechst 33342); Sigma-Aldrich).
4.7. Microarray Analysis
RNA was isolated from the freshly isolated human liver cells used for inoculation of the bioreactors
on Day 0 and from bioreactor cultures after termination of the cultures on Day 10. The isolation was
performed using RLT buffer (Qiagen, Hilden, Germany) with 1% 2-Mercaptoethanol (Sigma-Aldrich)
in conjunction with the RNeasy mini kit (Qiagen). Next, cDNA targets were prepared and labeled
using the IVT express kit and then hybridized on an Affymetrix® Human Genome U219 array plate
in the GeneTitan® instrument (Affymetrix, Santa Clara, CA, USA) according to the manufacturer’s
protocol. Gene expression microarray analysis of all time-points was performed using the Bioconductor
package version 2.12 (working with R version 3.0.1, [53]). Grouping of the individual probes into
gene-specific probe sets was based on Entrez Gene using the metadata package hgu219hsentrezg
(cdf version 19.0.0, [54]), assigning probes to 18539 genes. The robust multi-array average algorithm
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(RMA, [55]) was applied for preprocessing (probewise background correction, normalization and
probeset summarization). Differential gene expression at Day 10 of the bioreactor incubations was
analyzed using limma [56,57] using donor ID and/or dose groups as fixed factors. Multiple testing
correction was estimated using the method of Benjamini and Hochberg (False Discovery Rate
(FDR)) [58]. Pathway information was retrieved from the Gene Ontology Consortium [59]. Pathway
analysis is based on MLP [60] using the p-values of all genes from the differential analysis.
4.8. Statistics
Experiments were performed in triplicate and values are shown as means ˘ standard errors
of the mean (SEM). Statistical analyzes were performed using GraphPad Prism 5.0 for Windows
(GraphPad Software, San Diego, CA, USA). The influence of the drug dose (Day 3–10) on the metabolic
activity of the cells in comparison to the control was analyzed by means of one-way analysis of
variance (ANOVA) with Dunnett’s multiple comparison test. The course over time (Day 3–10) of
diclofenac metabolism was analyzed by linear regression analysis. Differences were judged as follows:
* = p < 0.05, ** = p < 0.01, *** = p < 0.001. For microarray analyses, genes with an adjusted p < 0.05 were
considered as differentially expressed in all comparisons unless mentioned otherwise.
5. Conclusions
In conclusion, transcriptional data in line with functional readouts clearly showed a dose-response
effect of diclofenac in the perfused bioreactor system. Thus, the data underscore the suitability of the
perfused 3D bioreactor system to perform long-term toxicity studies in vitro. In addition, the structure
of the bioreactor perfusion circuit allows for various flow modes mimicking the in vivo application of a
drug. In case of diclofenac a protocol simulating the continuous application of a drug over a longer
time period was established, but also toxicity studies with a single dose application are conceivable
without supplying fresh medium and introducing a bolus of the drug to the perfusion circuit. In
summary, the 3D bioreactor system represents a valuable tool for in vitro studies on hepatic drug
toxicity in humans.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/17/
4/584/s1.
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